AFF3 is a novel prognostic biomarker and a potential target for immunotherapy in gastric cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Laboratory Analysis"
DOI: 10.1002/jcla.24437
Abstract: Gastric cancer (GC) is one of the most common cancers worldwide with a poor prognosis. The tumor microenvironment (TME) serves a pivotal role in affecting the prognosis and efficacy of immunotherapy. Given the poor prognosis… read more here.
Keywords: biomarker potential; prognostic biomarker; novel prognostic; aff3 novel ... See more keywords